New York State Common Retirement Fund Decreases Position in ADMA Biologics Inc $ADMA

New York State Common Retirement Fund decreased its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 63.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 114,504 shares of the biotechnology company’s stock after selling 198,337 shares during the quarter. New York State Common Retirement Fund’s holdings in ADMA Biologics were worth $1,679,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Amalgamated Bank boosted its stake in ADMA Biologics by 0.8% during the 2nd quarter. Amalgamated Bank now owns 67,665 shares of the biotechnology company’s stock valued at $1,232,000 after purchasing an additional 540 shares during the last quarter. New York State Teachers Retirement System lifted its holdings in shares of ADMA Biologics by 0.3% during the second quarter. New York State Teachers Retirement System now owns 222,461 shares of the biotechnology company’s stock valued at $4,051,000 after purchasing an additional 571 shares in the last quarter. Quadrant Capital Group LLC boosted its position in shares of ADMA Biologics by 3.9% during the second quarter. Quadrant Capital Group LLC now owns 16,660 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 629 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of ADMA Biologics by 28.9% during the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 700 shares during the last quarter. Finally, Cerity Partners LLC increased its holdings in ADMA Biologics by 1.8% in the 2nd quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company’s stock worth $884,000 after buying an additional 869 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $16.43 on Monday. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $3.91 billion, a PE ratio of 19.10 and a beta of 0.49. The firm’s 50 day moving average price is $18.35 and its 200-day moving average price is $17.02. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $28.50.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.